Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 147 JPY -0.6% Market Closed
Market Cap: 32.8B JPY
Have any thoughts about
Daito Pharmaceutical Co Ltd?
Write Note

Daito Pharmaceutical Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Daito Pharmaceutical Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Daito Pharmaceutical Co Ltd
TSE:4577
Interest Income Expense
ÂĄ860m
CAGR 3-Years
31%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Interest Income Expense
-ÂĄ175.7B
CAGR 3-Years
-15%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Interest Income Expense
ÂĄ24.3B
CAGR 3-Years
100%
CAGR 5-Years
60%
CAGR 10-Years
8%
Otsuka Holdings Co Ltd
TSE:4578
Interest Income Expense
ÂĄ20.5B
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
Interest Income Expense
ÂĄ39m
CAGR 3-Years
-54%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Interest Income Expense
-ÂĄ1.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
No Stocks Found

Daito Pharmaceutical Co Ltd
Glance View

Market Cap
32.8B JPY
Industry
Pharmaceuticals

Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Intrinsic Value
2 433.41 JPY
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Daito Pharmaceutical Co Ltd's Interest Income Expense?
Interest Income Expense
860m JPY

Based on the financial report for Aug 31, 2024, Daito Pharmaceutical Co Ltd's Interest Income Expense amounts to 860m JPY.

What is Daito Pharmaceutical Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
64%

The average annual Interest Income Expense growth rates for Daito Pharmaceutical Co Ltd have been 31% over the past three years , 64% over the past five years .

Back to Top